These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 12871312)

  • 41. The P2Y(1) receptor as a target for new antithrombotic drugs: a review of the P2Y(1) antagonist MRS-2179.
    Baurand A; Gachet C
    Cardiovasc Drug Rev; 2003; 21(1):67-76. PubMed ID: 12595918
    [TBL] [Abstract][Full Text] [Related]  

  • 42. P2Y receptor antagonists in thrombosis.
    Boeynaems JM; van Giezen H; Savi P; Herbert JM
    Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of inhibition of P2Y(1) and P2Y(12) on whole blood clotting, coagulum elasticity and fibrinolysis resistance studied with free oscillation rheometry.
    Ramström S; Rånby M; Lindahl TL
    Thromb Res; 2003 Mar; 109(5-6):315-22. PubMed ID: 12818256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The P2Y1 receptor is necessary for adenosine 5'-diphosphate-induced platelet aggregation.
    Hechler B; Léon C; Vial C; Vigne P; Frelin C; Cazenave JP; Gachet C
    Blood; 1998 Jul; 92(1):152-9. PubMed ID: 9639511
    [TBL] [Abstract][Full Text] [Related]  

  • 45. P2Y1 receptors mediate apamin-sensitive and -insensitive inhibitory junction potentials in murine colonic circular smooth muscle.
    Zhang Y; Lomax AE; Paterson WG
    J Pharmacol Exp Ther; 2010 May; 333(2):602-11. PubMed ID: 20103587
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Acyclic and cyclopropyl analogues of adenosine bisphosphate antagonists of the P2Y1 receptor: structure-activity relationships and receptor docking.
    Kim HS; Barak D; Harden TK; Boyer JL; Jacobson KA
    J Med Chem; 2001 Sep; 44(19):3092-108. PubMed ID: 11543678
    [TBL] [Abstract][Full Text] [Related]  

  • 47. P2Y12 antagonist ticagrelor inhibits the release of procoagulant extracellular vesicles from activated platelets.
    Gasecka A; Nieuwland R; van der Pol E; Hajji N; Ćwiek A; Pluta K; Konwerski M; Filipiak KJ
    Cardiol J; 2019; 26(6):782-789. PubMed ID: 29671861
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Akt activation in platelets depends on Gi signaling pathways.
    Kim S; Jin J; Kunapuli SP
    J Biol Chem; 2004 Feb; 279(6):4186-95. PubMed ID: 14623889
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Anti-platelet therapy with clopidogrel prevents endothelial dysfunction and vascular remodeling in aortas from hypertensive rats.
    Giachini FR; Leite R; Osmond DA; Lima VV; Inscho EW; Webb RC; Tostes RC
    PLoS One; 2014; 9(3):e91890. PubMed ID: 24638017
    [TBL] [Abstract][Full Text] [Related]  

  • 50. ADP stimulates human endothelial cell migration via P2Y1 nucleotide receptor-mediated mitogen-activated protein kinase pathways.
    Shen J; DiCorleto PE
    Circ Res; 2008 Feb; 102(4):448-56. PubMed ID: 18174464
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Desensitization of endothelial P2Y1 receptors by PKC-dependent mechanisms in pressurized rat small mesenteric arteries.
    Rodríguez-Rodríguez R; Yarova P; Winter P; Dora KA
    Br J Pharmacol; 2009 Nov; 158(6):1609-20. PubMed ID: 19845669
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metabotropic P2Y1 receptors inhibit P2X3 receptor-channels in rat dorsal root ganglion neurons.
    Gerevich Z; Müller C; Illes P
    Eur J Pharmacol; 2005 Oct; 521(1-3):34-8. PubMed ID: 16181623
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Nucleotide coronary vasodilation in guinea pig hearts.
    Gorman MW; Ogimoto K; Savage MV; Jacobson KA; Feigl EO
    Am J Physiol Heart Circ Physiol; 2003 Sep; 285(3):H1040-7. PubMed ID: 12763753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Defective platelet aggregation and increased resistance to thrombosis in purinergic P2Y(1) receptor-null mice.
    Léon C; Hechler B; Freund M; Eckly A; Vial C; Ohlmann P; Dierich A; LeMeur M; Cazenave JP; Gachet C
    J Clin Invest; 1999 Dec; 104(12):1731-7. PubMed ID: 10606627
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Platelet responsiveness to yohimbine hydrochloride and MRS2179 in the context of the interaction between collagen and epinephrine in acute coronary syndrome.
    Lahiri P; Roy S; Sardar P; Deb S; Chakrabarti P; Guha P; Guha S; Chaudhuri U; Dasgupta AK
    Blood Cells Mol Dis; 2009; 43(1):105-10. PubMed ID: 19272818
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Platelet activation by ADP: the role of ADP antagonists.
    Gachet C
    Ann Med; 2000 Dec; 32 Suppl 1():15-20. PubMed ID: 11209975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A platelet target for venous thrombosis? P2Y1 deletion or antagonism protects mice from vena cava thrombosis.
    Bird JE; Wang X; Smith PL; Barbera F; Huang C; Schumacher WA
    J Thromb Thrombolysis; 2012 Aug; 34(2):199-207. PubMed ID: 22588534
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Human P2Y1 receptor: molecular modeling and site-directed mutagenesis as tools to identify agonist and antagonist recognition sites.
    Moro S; Guo D; Camaioni E; Boyer JL; Harden TK; Jacobson KA
    J Med Chem; 1998 Apr; 41(9):1456-66. PubMed ID: 9554879
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Platelet P2 receptors: old and new targets for antithrombotic drugs.
    Cattaneo M
    Expert Rev Cardiovasc Ther; 2007 Jan; 5(1):45-55. PubMed ID: 17187456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.